Skip to main content

Table 2 Symptom free days by country and ARIA severity

From: Burden of illness and quality of life in patients being treated for seasonal allergic rhinitis: a cohort survey

 

Total

FF

MF

FP

 

N

Mean (SD)

N

Mean (SD)

N

β

95% CI

N

β

95% CI

Symptom-free days

417

14.58 (8.42)

208

15.45 (8.29)

102

−1.22

−3.16 to 0.72

107

−1.95

−3.87 to −0.03

Country sub-groups

          

  France

152

14.45 (8.74)

75

16.15 (8.43)

36

−3.03

−6.37 to 0.32

41

−2.77

−6.03 to 0.49

  Germany

165

16.19 (7.70)

83

16.45 (7.74)

42

−0.81

−3.68 to 2.07

40

−0.59

−3.50 to 2.33

  Spain

100

12.12 (8.51)

50

12.74 (8.51)

24

1.48

−2.56 to 5.53

26

−0.98

−4.99 to 3.03

Severity sub-groups

          

  Mild intermittent

50

18.72 (8.34)

26

20.23 (7.69)

9

−1.77

−9.12 to 5.58

15

−2.30

−8.68 to 4.08

  Moderate/severe intermittent

138

15.21 (7.57)

74

15.05 (7.49)

38

1.44

−1.57 to 4.46

26

−1.76

−5.23 to 1.70

  Moderate/severe persistent

229

13.30 (8.62)

108

14.56 (8.62)

55

−2.50

−5.29 to 0.28

66

−1.95

−4.58 to 0.69

  1. FF: Fluticasone furoate; FP: Fluticasone propionate; MF: Mometasone furoate; β = adjusted mean difference from FF.